MHRA (UK)
OTHER
Class 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Published: 7/23/2026Detected: 7/23/2026
Summary preview
Notifies Class 4 medicine defect concerns relating to missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for specific batches of Tuzulby prolonged-release…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/4811/12/2026
- Field Safety Notices from 02 to 06 November2026.11/10/2026
- Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/5mL, EL(26)A/4611/5/2026
- Class 3 Medicines Recall: Aspire Pharma Limited, Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml , EL(26)A/4711/5/2026
- Field Safety Notices: 26 to 30 October 202611/4/2026